Related Experiment Video

Updated: Jan 16, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K

Discoidin domain receptor tyrosine kinase 2: A new perspective on microenvironment remodeling and targeted therapy of

Tong Lu1, Huiying Guo2, Hang Gong1

  • 1Department of Gastroenterology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.

Oncology Letters
|October 3, 2025
PubMed

Insights

Discoidin domain receptor tyrosine kinase 2 (DDR2) is a key target in cancer research. This review synthesizes recent advances in DDR2 research, highlighting its role in tumor progression and potential as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomedical Research

Background:

  • Cancer incidence is rising globally, necessitating novel therapeutic targets.
  • Despite advancements, a definitive cure for many cancers remains elusive.
  • Discoidin domain receptor tyrosine kinase 2 (DDR2) is implicated in various diseases and tumor progression.

Purpose of the Study:

  • To synthesize recent findings on discoidin domain receptor tyrosine kinase 2 (DDR2) research.
  • To assess the role of DDR2 across different tumor types.
  • To evaluate the significance of DDR2 in biomedical fields.

Main Methods:

  • Literature review of existing studies on DDR2.
  • Analysis of DDR2's involvement in tumor progression.
  • Synthesis of data on DDR2's emerging biomedical significance.

Main Results:

  • DDR2 plays a significant role in the progression of various cancers.
  • Recent research highlights DDR2 as a promising target for cancer therapy.
  • DDR2's involvement extends to multiple biomedical fields beyond oncology.

Conclusions:

  • DDR2 is a critical factor in cancer development and progression.
  • Targeting DDR2 presents a novel therapeutic strategy for cancer treatment.
  • Further research into DDR2 is crucial for advancing cancer therapy and biomedical applications.
Keywords:
cancerdiscoidin domain receptor tyrosine kinase 2inhibitormechanismsolid tumor

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.5K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.7K

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.8K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K